Glaukos : Investor Presentation August 2021

August 2021

Disclaimer

All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business or the economy generally; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, pandemic or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the iStent, the iStent inject, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our ability to compete effectively in the highly competitive and rapidly changing medical device industry and against current and future competitors (including MIGS competitors); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness.

These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for 2020, which was filed with the SEC on March 1, 2021, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, which was filed with the SEC on August 5, 2021. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward- looking statements included in this presentation are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

2 © 2021 Glaukos Corporation

Building a World-Class Global Infrastructure & Company

Significant Progress Continues Since 2015 IPO

TOTAL NET SALES (IN MILLIONS)		GROSS MARGIN1	75%		COUNTRIES WITH DIRECT SALES
			$225		2014
	6-Yr CAGR:						84%					2020
	30%					2021
															17
							CASH & EQUIVALENTS (IN MILLIONS)2			2014
$46					2015		$104				2
						2021			$428
	2014			2020

REVENUE MIX

Q2 2015

Q2 2021

US Glaucoma

Int'l Glaucoma

Corneal Health

PIPELINE PROGRAMS

2014 Disclosed Pipeline:

4 Glaucoma programs, including 1 pharma program

2021 Disclosed Pipeline:

15 Spans glaucoma, corneal health and retinal disease, including 10 pharma programs

PEER-REVIEWED PUBLICATIONS

300+

33 2021

2015

1 FY2014 GAAP & non-GAAP gross margin; 2Q 2021 GAAP gross margin of 77% was adjusted for certain Avedro merger-related accounting and other adjustments - see Appendix for details; 2 2015 as of 6/30/2015 (post-IPO); 2021 as of 6/30/2021; Includes cash, short-term investments and restricted cash;

3 © 2021 Glaukos Corporation

Our Strategy for Long-Term Growth & Profitability

Creating a Unique Vision Care Leader

MAJOR PLATFORMS

Micro-Scale

Surgical Devices

Pharmaceuticals

Biosensors

THERAPEUTIC CLASSES

Glaucoma Ocular Hypertension to Refractory Disease

Corneal	Keratoconus
Ocular Surface Disease
Health
Refractive Conditions

Retinal	Wet AMD
DME
Disease
RVO

4 © 2021 Glaukos Corporation

Our Strategy for Long-Term Growth & Profitability

Serving the Clinical Needs of Large Patient Populations

THERAPEUTIC CLASSES

Glaucoma Ocular Hypertension to Refractory Disease

Corneal	Keratoconus
Ocular Surface Disease
Health
Refractive Conditions

Retinal	Wet AMD
Disease	DME
	RVO

$13B $23B $13B

Est. of global opportunity1

Est. of US opportunity for keratoconus ($3B) and iLink for presbyopia ($15B), and est. of global annual dry eye market ($5.1B)2,3

Est. of global annual market size3

1 Estimate based on Glaukos algorithm of physician preference and combination therapy, utilization; assumes full product portfolio availability to physician, except pre-clinical products (iDose TREX, iDose Rock, IOP Sensor); 2 Company estimates of US opportunity; 3 Market Scope estimates

5 © 2021 Glaukos Corporation